Loading…

Catheter-directed thrombolysis for lower extremity deep vein thrombosis

The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulm...

Full description

Saved in:
Bibliographic Details
Published in:Techniques in vascular and interventional radiology 2001-06, Vol.4 (2), p.111-114
Main Author: Mewissen, Mark W
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3
cites cdi_FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3
container_end_page 114
container_issue 2
container_start_page 111
container_title Techniques in vascular and interventional radiology
container_volume 4
creator Mewissen, Mark W
description The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulmonary embolism but will also minimize the long-term sequelae of venous hypertension and the development of postthrombotic syndrome (PTS). Treatment strategies aimed at eliminating or reducing the risk of PTS should focus on preserving valvular function and eliminating the risk of continued venous obstruction after acute DVT. Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT.
doi_str_mv 10.1016/S1089-2516(01)90005-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71312627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1089251601900058</els_id><sourcerecordid>71312627</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMoVqs_QdmT6GE1sx_5OIkUrULBg3oOm90Jjew2NUmr_fduv_Doad6BZ2aYh5ALoLdAgd29ARUyzUpg1xRuJKW0TMUBOYGy5KkUVBz2eY8MyGkIn5T2uRTHZAAgBXDJT8h4VMUpRvRpYz3WEZskTr3rtGtXwYbEOJ-07ht9gj_RY2fjKmkQ58kS7WyP9uAZOTJVG_B8V4fk4-nxffScTl7HL6OHSVpnnMW0LjVQjQLLjBWmyCVbd7pArguWZwhUNoYZXkidC9NAVWmUXGagmawQTD4kV9u9c---Fhii6myosW2rGbpFUBxyyFjGe7DcgrV3IXg0au5tV_mVAqrWBtXGoFrrURTUxqAS_dzl7sBCd9j8Te2U9cD9FsD-zaVFr0JtcVbjVqBqnP3nxC_irIGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71312627</pqid></control><display><type>article</type><title>Catheter-directed thrombolysis for lower extremity deep vein thrombosis</title><source>Elsevier ScienceDirect Freedom Collection 2023</source><creator>Mewissen, Mark W</creator><creatorcontrib>Mewissen, Mark W</creatorcontrib><description>The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulmonary embolism but will also minimize the long-term sequelae of venous hypertension and the development of postthrombotic syndrome (PTS). Treatment strategies aimed at eliminating or reducing the risk of PTS should focus on preserving valvular function and eliminating the risk of continued venous obstruction after acute DVT. Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT.</description><identifier>ISSN: 1089-2516</identifier><identifier>EISSN: 1557-9808</identifier><identifier>DOI: 10.1016/S1089-2516(01)90005-8</identifier><identifier>PMID: 11981797</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Catheters, Indwelling ; Femoral Vein - pathology ; Femoral Vein - surgery ; Fibrinolytic Agents - therapeutic use ; Heparin - therapeutic use ; Humans ; Iliac Vein - pathology ; Iliac Vein - surgery ; Leg - blood supply ; Male ; Middle Aged ; Patient Selection ; Recombinant Proteins - therapeutic use ; Thrombolytic Therapy - instrumentation ; Thrombolytic Therapy - methods ; Tissue Plasminogen Activator - therapeutic use ; Treatment Outcome ; Venous Thrombosis - drug therapy</subject><ispartof>Techniques in vascular and interventional radiology, 2001-06, Vol.4 (2), p.111-114</ispartof><rights>2001</rights><rights>Copyright 2001 by W.B. Saunders Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3</citedby><cites>FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11981797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mewissen, Mark W</creatorcontrib><title>Catheter-directed thrombolysis for lower extremity deep vein thrombosis</title><title>Techniques in vascular and interventional radiology</title><addtitle>Tech Vasc Interv Radiol</addtitle><description>The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulmonary embolism but will also minimize the long-term sequelae of venous hypertension and the development of postthrombotic syndrome (PTS). Treatment strategies aimed at eliminating or reducing the risk of PTS should focus on preserving valvular function and eliminating the risk of continued venous obstruction after acute DVT. Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT.</description><subject>Catheters, Indwelling</subject><subject>Femoral Vein - pathology</subject><subject>Femoral Vein - surgery</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Heparin - therapeutic use</subject><subject>Humans</subject><subject>Iliac Vein - pathology</subject><subject>Iliac Vein - surgery</subject><subject>Leg - blood supply</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Selection</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Thrombolytic Therapy - instrumentation</subject><subject>Thrombolytic Therapy - methods</subject><subject>Tissue Plasminogen Activator - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Venous Thrombosis - drug therapy</subject><issn>1089-2516</issn><issn>1557-9808</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LAzEQhoMoVqs_QdmT6GE1sx_5OIkUrULBg3oOm90Jjew2NUmr_fduv_Doad6BZ2aYh5ALoLdAgd29ARUyzUpg1xRuJKW0TMUBOYGy5KkUVBz2eY8MyGkIn5T2uRTHZAAgBXDJT8h4VMUpRvRpYz3WEZskTr3rtGtXwYbEOJ-07ht9gj_RY2fjKmkQ58kS7WyP9uAZOTJVG_B8V4fk4-nxffScTl7HL6OHSVpnnMW0LjVQjQLLjBWmyCVbd7pArguWZwhUNoYZXkidC9NAVWmUXGagmawQTD4kV9u9c---Fhii6myosW2rGbpFUBxyyFjGe7DcgrV3IXg0au5tV_mVAqrWBtXGoFrrURTUxqAS_dzl7sBCd9j8Te2U9cD9FsD-zaVFr0JtcVbjVqBqnP3nxC_irIGE</recordid><startdate>200106</startdate><enddate>200106</enddate><creator>Mewissen, Mark W</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200106</creationdate><title>Catheter-directed thrombolysis for lower extremity deep vein thrombosis</title><author>Mewissen, Mark W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Catheters, Indwelling</topic><topic>Femoral Vein - pathology</topic><topic>Femoral Vein - surgery</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Heparin - therapeutic use</topic><topic>Humans</topic><topic>Iliac Vein - pathology</topic><topic>Iliac Vein - surgery</topic><topic>Leg - blood supply</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Selection</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Thrombolytic Therapy - instrumentation</topic><topic>Thrombolytic Therapy - methods</topic><topic>Tissue Plasminogen Activator - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Venous Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mewissen, Mark W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Techniques in vascular and interventional radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mewissen, Mark W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Catheter-directed thrombolysis for lower extremity deep vein thrombosis</atitle><jtitle>Techniques in vascular and interventional radiology</jtitle><addtitle>Tech Vasc Interv Radiol</addtitle><date>2001-06</date><risdate>2001</risdate><volume>4</volume><issue>2</issue><spage>111</spage><epage>114</epage><pages>111-114</pages><issn>1089-2516</issn><eissn>1557-9808</eissn><abstract>The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulmonary embolism but will also minimize the long-term sequelae of venous hypertension and the development of postthrombotic syndrome (PTS). Treatment strategies aimed at eliminating or reducing the risk of PTS should focus on preserving valvular function and eliminating the risk of continued venous obstruction after acute DVT. Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>11981797</pmid><doi>10.1016/S1089-2516(01)90005-8</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1089-2516
ispartof Techniques in vascular and interventional radiology, 2001-06, Vol.4 (2), p.111-114
issn 1089-2516
1557-9808
language eng
recordid cdi_proquest_miscellaneous_71312627
source Elsevier ScienceDirect Freedom Collection 2023
subjects Catheters, Indwelling
Femoral Vein - pathology
Femoral Vein - surgery
Fibrinolytic Agents - therapeutic use
Heparin - therapeutic use
Humans
Iliac Vein - pathology
Iliac Vein - surgery
Leg - blood supply
Male
Middle Aged
Patient Selection
Recombinant Proteins - therapeutic use
Thrombolytic Therapy - instrumentation
Thrombolytic Therapy - methods
Tissue Plasminogen Activator - therapeutic use
Treatment Outcome
Venous Thrombosis - drug therapy
title Catheter-directed thrombolysis for lower extremity deep vein thrombosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-10T05%3A31%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Catheter-directed%20thrombolysis%20for%20lower%20extremity%20deep%20vein%20thrombosis&rft.jtitle=Techniques%20in%20vascular%20and%20interventional%20radiology&rft.au=Mewissen,%20Mark%20W&rft.date=2001-06&rft.volume=4&rft.issue=2&rft.spage=111&rft.epage=114&rft.pages=111-114&rft.issn=1089-2516&rft.eissn=1557-9808&rft_id=info:doi/10.1016/S1089-2516(01)90005-8&rft_dat=%3Cproquest_cross%3E71312627%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c276t-c5b10be8e5264f43960be8b4e7b4632e109df6f749b38fd1aabe97921b69ae1f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71312627&rft_id=info:pmid/11981797&rfr_iscdi=true